Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Non-probability sampling: The study population consists of adult patients over the age of 18 affected by CHC who were previously treated for the first time with Peg-IFN alfa-2b plus ribavirin and achieved end-of-treatment response. Five hundred ninety patients must be recruited in order to evaluate the objectives of the study. The patients must meet all inclusion criteria and not meet any of the exclusion criteria in order to be included in the study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient must demonstrate his/her continued willingness to participate in the study.
The patient must be at least 18 years of age, of either gender.
Patients with chronic hepatitis C (any genotype) who received Peg-IFN alfa-2b + Ribavirin as first treatment for hepatitis C.
Negative HCV-RNA at the end of treatment (24 or 48 weeks according to the product labeling as appropriate), measured by the assay used at each institution. Only institutions using an assay with a limit of detection of 50 IU/mL or less will be eligible.
You may not be if
Patients who completed treatment with PegInterferon Alfa-2b plus Ribavirin more than 4 weeks before study entry.
Patients with positive HCV-RNA at the end of treatment (24 or 48 weeks according to the product labeling as appropriate).
Patients treated for a period shorter than the enrollment period.
Patients co-infected with human immunodeficiency virus (HIV).
Patients co-infected with hepatitis B virus (HBV).
Patients who do not use appropriate effective method of birth control after the end of treatment (according to legal recommendations).
